Background: Guidelines recommend antiretroviral therapy (ART) initiation at CD4 ,350 cells per microliter for HIV-infected individuals in resource-limited settings. However, funding for treatment expansion remains uncertain. We forecast the mortality impact of ART expansion alternatives in Haiti.
INTRODUCTION
Major donor initiatives to combat HIV along with increasing in-country commitments to curb the epidemic have facilitated rapid HIV treatment scale-up in low-and middleincome countries. 1 However, although a minority of countries have achieved universal antiretroviral therapy (ART) access or coverage targets of 80% or higher, these targets remain challenging in many settings. 1 The global economic crisis and waning international political commitment to HIV prevention and treatment efforts globally have contributed to declines in donor disbursements for ART provision and decreasing country-level budgets. 2, 3 Diminishing resources for HIV treatment occur against a backdrop of increased need for ART because of efforts to improve case identification and retention in care 4 ; demonstrated survival benefit among those receiving ART 5, 6 ; revised World Health Organization (WHO) guidelines calling for earlier ART initiation 7, 8 ; and new clinical evidence that ART decreases the risk of transmitting HIV. 9, 10 Limited funding, health system, and social service capacity to address the increasing demand for ART will require country-specific policy decisions at the national level. Haiti, a poor Caribbean country with a per capita income of approximately US $650 annually, 11 has mounted a successful response to the HIV/AIDS epidemic with assistance from international donors, similar to other resource-limited settings. For example, evidence suggests that HIV prevalence in Haiti has declined over the past decade, 12 with the percentage of Haitian adults, aged 15-49 years, living with HIV currently at about 1.9%. 13 WHO estimates that of those medically eligible for treatment according to current WHO guidelines, 7 the number of HIV-infected individuals receiving ART in Haiti has increased significantly, from 5% in 2004 to more than 40% in 2009. 14 Despite these gains, however, funding in Haiti and other low-income settings remains limited. For example, US President's Emergency Plan for AIDS Relief funds allocated to Haiti decreased from US $164.1 million in fiscal year 2010 to US $158.5 million in fiscal year 2011. 15 Global Fund disbursements to Haiti remained relatively flat in 2011 and 2012 at approximately US $15.5 million. 16 Future availability of resources for expanded treatment according to current WHO guidelines (ie, ART initiation at WHO stages III-IV or CD4 count ,350 cells per microliter) versus previous guidelines (ie, ART initiation at WHO stage IV or CD4 count ,200 cells per microliter) is uncertain. In this context, our objective was to forecast the potential lives saved resulting from further ART expansion in Haiti, potential lives lost as a result of not continuing to expand ART availability, and fraction of those eligible to receive ART with and without further expansion.
METHODS

Analytic Overview
We developed a multicohort mathematical model of untreated and treated HIV disease in Haiti. The model assesses 2 policy-relevant eras of HIV/AIDS treatment: (1) antiretroviral scale-up between 2004 and 2009 and (2) 10-year policy projections beginning in 2010, reflecting a period of funding uncertainty for HIV treatment. Model inputs were estimated from 30 years of well-characterized natural history cohort data, ART cohort data, and a randomized trial of early versus delayed ART, all collected from the Haitian Study Group for Kaposi's Sarcoma and Opportunistic Infections (GHESKIO) clinic in Port-au-Prince, Haiti. 8, [17] [18] [19] [20] [21] [22] Additional model inputs came from a model verification process informed by country-level reports from Haiti on ART scale-up between 2004 and 2009. 13 We evaluated the performance of alternative ART expansion scenarios at the population level, including the total number of deaths and HIV-infected individuals alive, the number receiving ART, and ART coverage, defined as the fraction of those eligible to receive ART who receive it. We conducted sensitivity analyses to assess the impact of uncertain model input parameters and policy-related variables on our results. The model is implemented in Microsoft Excel 2010 (Microsoft Corporation, Redmond, Washington) (Additional methodological details are available in the Supplemental Digital Content, http://links.lww.com/QAI/A412).
Scenarios
We evaluated 5 ART initiation scenarios: (1) No New ART initiation (worst case), (2) Restricted ART capacity to current treatment levels (Fixed Capacity), (3) †In this scenario, individuals eligible to initiate ART with intermediate HIV still face competing risks for other clinical events, including pre-ART loss from care, disease progression to AIDS before ART initiation, and AIDS-and non-AIDS-related mortality. Therefore, in this scenario, the upper bound of the increased annual probability of initiating ART with intermediate HIV is estimated based on the annual probabilities of the competing risks.
‡In this scenario, individuals eligible to initiate ART with intermediate HIV or experiencing AIDS still face competing risks for other clinical events, including pre-ART loss from care, disease progression to AIDS before ART initiation, and AIDS-and non-AIDS-related mortality. Therefore, the annual probability of initiating ART when experiencing AIDS remains less than 1. also evaluate a No ART scenario, in which we assumed that no ART was available for HIV-infected individuals in Haiti.
The scenarios were defined to reflect the current situation in Haiti and other resource-poor countries with constrained budgets in several ways. First, in accordance with the international guidelines and clinical practice in Haiti, individuals are treated with up to 2 sequential ART regimens, receive semiannual CD4 tests, and have quarterly clinic visits unless otherwise clinically indicated. 7 Second, disease progression in individuals receiving ART varies based on when, in the course of disease, ART is initiated, with ART initiation earlier in the course of disease (eg, at CD4 count ,350 cells per microliter) associated with less rapid disease progression and improved health outcomes. 8 Third, detection of ART failure and switching to second-line therapy occurs based on clinical and immunologic monitoring of treatment response in HIV-infected patients. 7 In addition, individuals who are in care but not receiving ART have a decreased risk of disease progression and mortality compared with those who are not in care, including those who are lost. 23, 24 Finally, once an HIV-infected individual is lost from treatment and/or care, the individual is not eligible to return and is assumed to follow natural history disease progression until death. Although this assumption may be a simplification, the literature suggests a high risk of mortality among patients lost from ART programs in resource-limited settings. 25 
Model Structure
We developed a state-transition (Markov) model for multiple cohorts of treated and untreated HIV-infected individuals. 8, 13, [17] [18] [19] [20] [21] The model is defined by a set of 12 mutually exclusive and collectively exhaustive health states. Movement between health states occurs probabilistically through a series of possible events within an annual model cycle. 26, 27 For each cohort, the model simulates strategy-specific clinical disease progression and mortality that varies depending on engagement with clinical care over time. Cohorts of hypothetical prevalent and newly HIV-infected patients progress through mutually exclusive stages of untreated disease ( Fig. 1 , with inputs adjusted such that outcomes approximate the historical data available from Haiti during this time frame. 28 The model then forecasts scenario-specific outcomes for the policy projection period, 2010-2020. Annual outcomes are summed across the cohorts in terms of mortality, number of individuals on ART, and ART coverage for each of the HIV treatment expansion scenarios. 
Model Input Parameter Estimation
We used patient-level data from 3 Haitian observational cohorts and a randomized, controlled trial conducted in Haiti to derive model inputs-in the form of transition probabilitiesfor treated and untreated disease progression of individual cohorts (Table 2) 19, 21, 22 To derive model inputs for individuals initiating ART with AIDS, patient-level data came from 408 patients in the early treatment group of the CIPRA HT-001 randomized, controlled trial of early versus delayed ART conducted at GHESKIO. 8 To derive the model inputs, we performed incidence density analysis of the patient-level data and estimated event rates. Event rates were calculated by summing the total number of events (eg, the number lost from ART conditional on ART initiation at CD4 count ,200 cells per microliter, the number of untreated individuals with CD4 count 200-350 cells per microliter progressing to AIDS), relative to the total person-time at risk for the event. In deriving the event rates from the patient-level data, subjects who were event free were right censored at death, the end of the study, or the last documented clinic visit if lost from care or transferred to another care facility. 29 Following typical practice, censoring was considered independent and non-informative, such that individuals who were fully followed (and therefore not censored) during the study period were similar to those who were not fully followed (or censored). The patient-level data were analyzed using STATA software, release 11 (StataCorp, College Station, TX). We calculated annual event rates to correspond with the model's annual cycle length. We assumed that the number of events from the patient-level data occurred in a Poisson process (ie, continuously, independently, and at a constant rate) with time between events having an exponential distribution, allowing conversion of the event rates to probabilities for use as inputs in the model. 30 Additional model inputs were derived from a model verification process involving calibration of the model to population-level data from Haiti. 28 We first identified uncertain model inputs, including the number of newly HIVinfected individuals annually and their engagement with clinical care (ie, probabilities of linkage to care, pre-ART retention in care, and ART enrollment). Next, multiple uncertain model input parameters were systematically and simultaneously varied. We then identified those input values resulting in model estimates of the number on ART annually that minimized the percent deviation between model predictions and historical data on the number receiving ART annually in Haiti. At the time this analysis was conducted, national data on the number receiving ART annually were available for 2004-2009. 13 Finally, the means of the input values represented in the best-fitting parameter sets were used as model 
Analysis
One-way sensitivity analyses were conducted to evaluate the impact on results of uncertainty in model input parameters and in policy-related variables, including natural history disease progression, antiretroviral effectiveness, and HIV incidence ( Table 2 ). Ranges were defined by the 95% confidence intervals derived from the patient-level data, estimated bounds for both population-level inputs and parameters derived during the model verification process, or by 625% for the adjusted disease progression parameters. 8, 14, [17] [18] [19] [20] [21] [22] 28 We also conducted several targeted sensitivity analyses to reflect clinically and policy-relevant concerns that may affect health outcomes and be important to decision makers. First, we varied the time of detection of first-line antiretroviral failure and switching to second-line ART and, in turn, mortality risk on second-line ART, reflecting potential earlier detection by using new HIV RNA monitoring technologies (HIV RNA monitoring for earlier ART failure detection, Table 2 ). 31 Second, we considered the effects of ART on HIV transmission 9, 10 by linearly decreasing the number of newly HIV-infected annually between 1% and 20%. Finally, we assessed the impact of simultaneous policies that increased HIV testing and linkage to care and retention in treatment and care (optimal policy improvement, Table 2 ). 7, 32 ) will increase the number on ART by 5400 (+12.9%) and avert 3000 deaths (-3.3%) by 2020. The Full Expansion scenario will increase the number on ART by 7400 (+17.1%) and avert 4300 deaths (24.8%) by 2020. Restricting ART initiation to achieve constant ART capacity will reduce the number on ART by 15,700 (236.3%) and result in 10,200 (+11.4%) additional cumulative deaths, whereas No New ART initiation will reduce the number on ART by 25,600 (259.1%) and increase cumulative deaths by 15,200 (+16.9%).
RESULTS
Verification of Model
By 2020, ART coverage according to current guidelines will reach 62.1% with Full Expansion, compared with 56.0% with expansion at current rates and 28.7% in the No New ART scenario. The number of HIV-infected individuals in care and eligible for, but not receiving, ART will fall to 6500 with Full Expansion compared with 8600 at current rates and 16,200 in the No New ART scenario. With predicted cumulative deaths ranging from 85,400 (best case) to 104,900 (worst case), the model estimates as many as 19,500 lives could be saved through ART expansion over the next decade. This is equivalent to nearly 20% of the number of individuals estimated to be living with HIV in Haiti in 2010.
Sensitivity Analysis
When univariate sensitivity analyses were conducted to assess the impact of uncertainty in the model parameters, results are most sensitive to HIV incidence, untreated HIV disease progression, and the probability of pre-ART loss from care (see Tables S2-S4 and Figure S2 , Supplemental Digital Content, http://links.lww.com/QAI/A412). Variation in these parameters had a greater impact on treatmentrelated outcomes (eg, ART coverage) than survival. For example, given the range of estimates for the number newly infected annually, ART coverage estimates vary from 212.8% to +4.4% (ie, ART coverage 25%-65%) for the No New ART (worst case) and Full Expansion (best case) scenarios, respectively. In contrast, estimated deaths vary from 25.4% to +6.4% (ie, 4600-6700 cumulative deaths) for the worst and best scenarios. Results are less sensitive to disease progression on ART and HIV testing and linkage to care.
We also conducted targeted sensitivity analyses to reflect specific concerns important to decision makers. We found that results are not sensitive to assumptions regarding earlier detection of antiretroviral failure and switching to second-line ART and lower mortality on second-line ART, resulting from HIV RNA treatment monitoring for patient management. For example, cumulative deaths over 10 years decreased by 1500 to 103,400 (21.4%) for the No New ART scenario and by 1900 to 85,400 (22.2%) for the Full Expansion scenario. Decreasing HIV incidence over time to reflect the prevention benefit of ART reduces cumulative deaths across all strategies over the analytic time horizon. The mortality difference between the Full Expansion and No New ART scenarios declines from 19,500 (base case) to 19,400 (1% decrease in the number newly infected annually) to 17,600 (20% annually) *Values shown for disease progression, linkage to care and treatment, pre-ART loss from care, loss from treatment, and selected sensitivity analyses are annual probabilities. Ranges for the model inputs reflect the upper and lower bounds used in 1-way sensitivity analyses, which assessed the impact of uncertainty in the parameter estimates on model results. Values used in the targeted sensitivity analyses, which are intended to reflect programmatic and policy decisions that may affect health outcomes and which are important to decision makers, are shown later in the table.
†Model input values and associated ranges were obtained from the model verification process, which was used to confirm that model projections correspond with historical data on ART scale-up in Haiti. 13 The process involves systematically varying multiple, uncertain model input parameters and identifying the input values resulting in model outcomes that best approximate empirical data. 28 Additional information on this process is available in the Methods. ‡Between 2005 and 2009, model predictions (versus the WHO's estimated range) for the number of newly HIV-infected individuals annually were 11,000 (8100-13,000), 10,100 (7700-12,000), 10,200 (7000-12,000), 9200 (6800-12,000), and 8600 (6500-11,000), respectively.
§The range for this input parameter represents 625% of the base case value. ¶The optimal policy improvement included (a) HIV testing and linkage to care equal to the upper bound of the estimated bounds derived during the model verification process, regardless of disease stage; (b) pre-ART loss from care equal to the lower bound of the estimated bounds derived during the model verification process for all individuals in the asymptomatic and intermediate disease stages; and (c) loss from treatment equal to the lower bound of the estimated bounds derived during the model verification process, regardless of the disease stage in which they initiated ART. Pre-ART loss from care for individuals in the AIDS disease stage was assumed to be 0.02, which is within the range of the estimated bounds derived during model verification.
kIn the HIV RNA monitoring sensitivity analysis, a 3.8-fold increase in the rate of first-line antiretroviral failure and switching to second-line ART was applied to individuals receiving ART initiated at CD4 ,200 cells per microliter. 32 The second-line ART mortality risk among those initiating ART at CD4 ,200 cells per microliter was equivalent to the mortality risk of those on first-line ART .12 months.
Asymptomatic cumulative deaths averted over 10 years. ART coverage for all scenarios increases as the annual percent decrease in HIV incidence increases.
An optimal policy improvement in which HIV testing and linkage to care and retention in treatment and care are simultaneously improved results in 52,300 on ART by 2020 and 86,400 cumulative deaths over 10 years, if ART initiation continues at current rates (Table 3, "Current Rates" refers to the probability of ART initiation remaining fixed at 2010 levels. "Limited Expansion" refers to the increased probability of ART initiation for patients with CD4 counts 200 -350 cells per microliter in order to implement the change from previous to current WHO guidelines, whereas "Full Expansion" refers to all patients in care and eligible for treatment initiating ART. 7, 32 1 can begin to be realized in Haiti but requires taking additional, simultaneous steps to improve engagement with clinical care, including case identification and linkage to care, pre-ART retention in care, and retention on treatment, in addition to efforts to increase treatment expansion.
Findings from this analysis can inform country-level, HIV-related planning efforts in resource-limited settings. Enrolling new patients on ART at rates that reflect scale-up under the previous WHO HIV treatment guidelines 32 (ie, according to the Current Rates scenario) will require nearly 60% more treatment slots in 10 years. Implementing the current WHO HIV treatment guidelines 7 at a level consistent with previous scale-up (ie, the Limited Expansion scenario) will require over 75% more treatment slots in 10 years, whereas enrollment of all treatment-eligible individuals on ART will require approximately 85% more treatment slots at the end of this decade. Efficiency improvements in care delivery (eg, integration of care across disease domains, task delegation), continued donor funding along with country-level financial sustainability plans, and human resource capacity building will need to be addressed simultaneously if treatment capacity increases are to continue. 33 In addition to continued treatment expansion, improvements in case identification and linkage to care, retention in pre-ART care, and retention on ART will all be required to increase ART coverage. This analysis suggests that these complementary efforts should focus in particular on retaining HIV-infected patients in care once identified and linked to care but before initiating ART. In the current analysis, along with a policy of full treatment expansion and efforts to improve case identification and treatment retention, increases in pre-ART retention of more than 70% were required to begin to achieve universal ART coverage. Similar opportunities for improvement regarding pre-ART retention in care exist in sub-Saharan African settings, 34 even though challenges remain to effectively retain newly diagnosed individuals in care. There may be a similar potential benefit from improved retention on treatment in settings other than Haiti. 35 We interpret our findings in the context of recent reports of the number on ART in Haiti. As of May 2012, 37,841 individuals were actively on ART in Haiti (written personal communication with JW Pape, MD, dated July 19, 2012) , which is consistent with the results from the increasing capacity and policy improvement scenarios considered in the current analysis. Treatment expansion and other policy improvements not only will increase the number on ART and ART coverage but may also reduce tuberculosis-associated mortality and prevent new cases of tuberculosis, particularly when ART is initiated earlier in disease progression. 36 As data on these benefits continue to emerge, the model can be updated to provide additional insight into the health impact of treatment expansion. Our analysis has several limitations. First, we assume that regimen-specific treatment effectiveness is fixed over the 10-year policy projection period. However, given the relatively short analytic time horizon, it is unlikely that improvements in ART effectiveness would have major impact on our policy conclusions that are driven by mortality among those who lack access to care. Second, the analysis does not consider changes in adherence to ART over time. Although changes in adherence could affect mortality in this population, 37 ,38 these effects would not be seen at the community level over the analysis period. Third, our projections reflected the adult HIV-infected population in Haiti and did not explicitly include HIV-infected children. Finally, the current analysis does not explicitly account for population-level disease dynamics. Despite recent evidence indicating ART may decrease the risk of HIV transmission at the patient level, 9, 10 there was a relatively small impact on our results across strategies when we reduced the number of new HIV infections for the duration of our forecast.
This analysis suggests that expanding access to ART will save lives and that near-universal access may be achievable. This will require a better understanding by HIV care providers and funders of how treatment-related resources can be more effectively and efficiently targeted to achieve these goals, including providing an adequate workforce, sufficient health-care facilities, and necessary logistics support. Efforts to sustain international financing for ART must be coupled with strategies to improve health system efficiency to prevent avoidable deaths and increase access to ART.
